Breast Cancer
📧 Sign up to get email alerts when something new happens for Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2020-09-04Clinical Trial Update: A Study to Assess Preference for Subcutaneous Trastuzumab Treatment in Participants With Human Epidermal Growth Factor Receptor (HER)2-Positive Metastatic Breast Cancer Responding to First-Line Intravenous Trastuzumab for at Least 3 Years [Phase 3]
Phase 3 trial updating preference for subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients respond…
-
CLINICAL_TRIALS trial_result · 2020-09-03Clinical Trial Update: Study of Tislelizumab Plus Chemotherapy vs Chemotherapy as Perioperative Treatment in Participants With HER2 Negative Breast Cancer [Phase 2]
Phase 2 trial evaluating tislelizumab plus chemotherapy versus chemotherapy as perioperative treatment in HER2-negative breast cancer.
-
CLINICAL_TRIALS trial_result · 2020-09-02Clinical Trial Update: Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer [Phase 2]
Phase 2 trial of seribantumab plus fulvestrant in postmenopausal women with metastatic breast cancer was terminated; results posted in 2020.
-
FDA approval · 2020-09-01FDA Approved: PIQRAY — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for PIQRAY (alpelisib) from Novartis Pharmaceuticals Corporation. This action approves the reque…
-
CLINICAL_TRIALS trial_result · 2020-08-27Clinical Trial Update: A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients [Phase 3]
Phase III trial comparing niraparib to physician's choice in HER2-negative, germline BRCA mutation–positive breast cancer terminated; result…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-08-25Clinical Trial Update: BrUOG 291: Five Fraction Partial Breast Irradiation Using Non-invasive Image-guided Breast Brachytherapy (NIBB) [NA]
Clinical trial update for BrUOG 291 assessing five-fraction partial breast irradiation using non-invasive image-guided breast brachytherapy …
-
CLINICAL_TRIALS trial_result · 2020-08-24Clinical Trial Update: Dexmedetomidine or Dexmedetomidine Combined With Dexamethasone on Postoperative Nausea and Vomiting in Breast Cancer [NA]
A completed clinical trial evaluating dexmedetomidine alone or with dexamethasone for postoperative nausea and vomiting in breast cancer sur…
-
FDA approval · 2020-08-20FDA Approved: VINORELBINE — Supplemental Application (Sagent Pharmaceuticals)
FDA approved a supplemental application for VINORELBINE (vinorelbine) from Sagent Pharmaceuticals.
-
FDA approval · 2020-08-20FDA Approved: LETROZOLE — Supplemental Application (Natco Pharma Limited)
FDA issued a supplemental approval for Natco Pharma Limited's generic letrozole under an ANDA. Letrozole is used to treat hormone receptor-p…
-
FDA approval · 2020-08-18FDA Approved: TOREMIFENE CITRATE — Original Application (Novadoz Pharmaceuticals LLC)
FDA approved a generic version of toremifene citrate through an original ANDA submitted by Novadoz Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2020-08-18Clinical Trial Update: Eribulin Plus Cisplatin Versus Gemcitabine Plus Cisplatin in Triple Negative Breast Cancer (TNBC) [Phase 2]
Phase 2 trial comparing eribulin plus cisplatin versus gemcitabine plus cisplatin in triple-negative breast cancer is reported as ongoing wi…
-
CLINICAL_TRIALS trial_result · 2020-08-18Clinical Trial Update: Radiation Therapy in Treating Patients With Recurrent Breast Cancer [NA]
Clinical trial update for radiation therapy in recurrent breast cancer; study status completed with results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-14Clinical Trial Update: Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer [Phase 3]
Phase 3 trial evaluating doxorubicin, cyclophosphamide, and paclitaxel with or without trastuzumab in HER2-positive breast cancer; study com…
-
CLINICAL_TRIALS trial_result · 2020-08-14Clinical Trial Update: Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating vinorelbine and docetaxel in women with metastatic breast cancer has completed.
-
CLINICAL_TRIALS trial_result · 2020-08-14Clinical Trial Update: Accelerated Intensity Modulated Radiation Therapy (AIMRT) to the Breast After Segmental Mastectomy [NA]
Completed clinical trial evaluating accelerated intensity modulated radiation therapy to the breast after segmental mastectomy for breast ca…
-
FDA approval · 2020-08-14FDA Approved: TAMOXIFEN CITRATE — Original Application (Aurobindo Pharma Limited)
FDA approved Aurobindo Pharma Limited's Original Application for Tamoxifen Citrate, a generic version of tamoxifen.
-
CLINICAL_TRIALS trial_result · 2020-08-13Clinical Trial Update: Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer [Phase 2, Phase 3]
A neoadjuvant treatment approach guided by response is being studied in HER2-positive breast cancer across Phase 2 and Phase 3 trials.
-
CLINICAL_TRIALS trial_result · 2020-08-13Clinical Trial Update: A Study of Abemaciclib (LY2835219) With and Without Food in Participants With Metastatic Breast Cancer [Phase 2]
Phase 2 study evaluating abemaciclib (LY2835219) with and without food in metastatic breast cancer has completed; results posted.
-
CLINICAL_TRIALS trial_result · 2020-08-10Clinical Trial Update: A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation [Phase 3]
Phase 3 clinical trial updating the study of Fluzoparib with or without Apatinib versus chemotherapy in HER2-negative metastatic breast canc…
-
CLINICAL_TRIALS trial_result · 2020-08-10Clinical Trial Update: Enzastaurin in Combination of Capecitabine to Treat Breast Cancer [Phase 2]
Phase 2 trial of enzastaurin in combination with capecitabine for breast cancer was terminated; results posted in 2020.
-
CLINICAL_TRIALS trial_result · 2020-08-10Clinical Trial Update: Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast Cancer [Phase 2]
Phase 2 trial comparing radium-223 dichloride to placebo with hormonal therapy in bone-predominant HER2-negative, hormone receptor-positive …
-
FDA approval · 2020-08-07FDA Approved: LETROZOLE — Supplemental Application (Natco Pharma Limited)
FDA approves Natco Pharma Limited's supplemental application for letrozole (generic). This action updates the labeling/approval status of th…
-
FDA approval · 2020-08-07FDA Approved: FULVESTRANT — Original Application (Dr.Reddy's Laboratories Inc)
FDA approves Dr. Reddy's Laboratories' generic Fulvestrant through an Original Application (ANDA).
-
CLINICAL_TRIALS trial_result · 2020-08-06Clinical Trial Update: Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) [Phase 3]
Phase 3 trial comparing nanoparticle-based paclitaxel to solvent-based paclitaxel as part of neoadjuvant chemotherapy in early breast cancer…
-
CLINICAL_TRIALS trial_result · 2020-08-06Clinical Trial Update: Mechanistic Study of Duloxetine in Breast Cancer Patients With Chronic Pain [Phase 2]
Phase 2 mechanistic study of duloxetine in breast cancer patients with chronic pain has completed and results posted.